DOCSLIB.ORG

Κδπ 63/1983, Επικυρωτικό Διάταγμα 1983, Για Τον Πίνακα

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Κδπ 63/1983, Επικυρωτικό Διάταγμα 1983, Για Τον Πίνακα Κ.Δ.Π. 63/83 ΠΑΡΑΡΤΗΜΑ ΤΡΙΤΟ ΤΗΣ ΕΠΙΣΗΜΗΣ ΕΦΗΜΕΡΙΔΑΣ ΤΗΣ ΔΗΜΟΚΡΑΤΙΑΣ Αρ. 1851 της 26ης ΜΑΡΤΙΟΥ 1983 ΔΙΟΙΚΗΤΙΚΕΣ ΠΡΑΞΕΙΣ ΜΕΡΟΣ Ι Κανονιστικές Διοικητικές Πράξεις Αριθμός 63 ΟΙ ΠΕΡΙ ΦΑΡΜΑΚΩΝ (ΕΛΕΓΧΟΣ ΠΟΙΟΤΗΤΟΣ, ΠΡΟΜΗΘΕΙΑΣ ΚΑΙ ΤΙΜΩΝ) ΝΟΜΟΙ ΤΟΥ 1967 ΚΑΙ 1980 (ΝΟΜΟΙ 6 ΤΟΥ 1967 ΚΑΙ 30 ΤΟΥ 1980) Διάταγμα σύμφωνα με το άρθρο 14 Επειδή το Συμβούλιο Φαρμάκων ετοίμασε και μου υπέβαλε Πίνακα που περιέχει τα φάρμακα που θα θεωρούνται ότι χρειά­ ζονται συνταγή για σκοπούς του Μέρους IV των περί Φαρμάκων (Έλεγχος Ποιότητος, Προμηθείας και Τιμών) Νόμων του 1967 και 1980. Γι' αυτό το λόγο, ασκώντας τις εξουσίες που μου παρέχονται από το εδάφιο (3) του άρθρου 14 του Νόμου, με το παρόν διατάσσω τα ακόλουθα: 1. Το Διάταγμα αυτό θα αναφέρεται ως το Επικυρωτικό Διάτα­ γμα του 1983, για τον Πίνακα των Φαρμάκων που χρειάζονται συνταγή. 2. Ο Πίνακας Φαρμάκων που χρειάζονται συνταγή και που φαί­ νεται στο Παράρτημα με το Διάταγμα αυτό επικυρώνεται. 3. Το Επικυρωτικό Διάταγμα του 1970 για τον Πίνακα Φαρμάκων Επίσημη που χρειάζονται συνταγή με το Διάταγμα αυτό ακυρώνεται. εφημερίδα, Τρίτο: 10.4.1970, (163) - 164 ΠΑΡΑΡΤΗΜΑ ΠΙΝΑΞ ΧΡΗΖΟΝΤΩΝ ΣΥΝΤΑΓΗΣ ΦΑΡΜΑΚΩΝ ΜΕΡΟΣ Ι Ακεβουτολόλη υδροχλωρική (Acebutolol hydrochloride). Ακεπρομαζίνη (Acepromazine). Ακεπρομαζίνη μηλεϊνική (Acepromazine maleate). Ακετανιλίδιον (Acetanilide). Ακεταρσόλη (Acetarsol). Ακεταζολαμίδιον (Acetazolamide). Ακεταζολαμίδιον νατριούχον (Acetazolamide sodium). Ακετοεξαμίδιον (Acetohexamide). Ακετυλοκαρβρωμάλη (Acetylcarbromal). Ακετυλοχολίνη χλωριούχος (Acetylcholine chloride) πλην εξωτερική χρήσις Μ.Π. 0.2% Ακετυλοκυστεΐνη (Acetylcysteine). Ακετυλοδιγιτοξίνη (Acetyldigitoxin). Ακετυλοστροφανθιδίνη (Acetylstrophanthidin). Ακετυλοσουλφαφουραζόλη (Acetyl sulphafurazole). Ακετυλοσουλφαμεθοξυπυριδαζίνη (Acetyl sulphamethoxypyridazine). Ακονιτίνη (Aconitine) πλην εξωτερική χρήσις Μ.Π. 0.02% Ακονιτίνη υδροβρωμική (Aconitine hydrobromide) πλην εξωτερική χρήσις Μ.Π. 0.02% (ως βάσις) Ακονιτίνη υδροχλωρική (Aconitine hydrochloride) πλην ως ακονιτίνη υδροβρωμική. Ακονιτίνη νιτρική (Aconitine nitrate) πλην ως ακονιτίνη υδροβρωμική. Ακονίτου ρίζα (Aconite root) πλην εξωτερική χρήσις Μ.Π. 1.3%. Ακτινομυκίνη C (Actinomycin C). Ακτινομυκίνη D (Actinomycin D). Ακυκλοβίρη (Acyclovir). Αδικιλλίνη (Adicillin). Αδιφαινίνη υδροχλωρική (Adiphenine hydrochloride Αδρεναλίνη (Adrenaline) πλην εξωτερική χρήσις και δι' εισπνοάς. Αδρεναλίνη τρυγική όξινος (Adrenaline acid tartrate) πλην ως αδρεναλίνη. Αδρεναλίνη υδροχλωρική (Adrenaline hydrochloride) πλην ως αδρεναλίνη. Ακλομίδιον (Aklomide). Αλκλοφαινάκη (Alclofenac). Αλκουρώνιον χλωριούχον (Alcuronium chloride). Αλδοστερόνη (Aldosterone). Αλφακαλκιδόλη (Alfacalcidol). Αλγεστόνη (Algestone). Αλγεστόνης ακετονίδιον (Algestone acetonide). Αλγεστόνης ακετοφαινίδιον (Algestone acetophenide). Αλλοβαρβιτόνη (Allobarbitone). Αλλοπουρινόλη (Allopurinol). Αλλυλοεστρενόλη (Allyloestrenol). Αλφαδολάνη οξική (Alphadolone acetate). Αλφαξαλόνη (Alphaxalone). Αλπραζολάμη (Alprazolam). Αλπρενολόλη (Alprenolol). Αλπρενολόλη υδροχλωρική (Alprenolol hydrochloride). Αλσερόξυλον (Alseroxylon). Αλτιζίδιον (Altizide). 165 Αμανταδίνη υδροχλωρική (Amantadine hydrochloride). Αμβενώνιον χλωριούχον . (Ambenonium chloride). Αμβουσίδιον (Ambuside). Αμβουτώνιον βρωμιούχον (Ambutonium bromide). Αμκινονίδιον (Amcinonide). Αμεταζόλη υδροχλωρική (Ametazole hydrochloride). Αμεθοκαΐνη (Amethocaine) πλην οιαδήποτε χρήσις επί ανθρώπων εκτός οφθαλμικής και οιαδήποτε κτηνιατρική χρήσις). Αμεθοκαΐνη γεντισική (Amethocaine gentisate) πλην ως αμεθοκαΐνη. Αμεθοκαΐνη υδροχλωρική (Amethocaine hydrochloride) πλην ως αμεθοκαΐνη. Αμιδοπυρίνη (Amidopyrine). Αμικακίνη θειική (Amikacin sulphate). Αμιλορίδιον υδροχλωρικόν (Amiloride hydrochloride). Αμινοκαπροϊκόν οξύ (Aminocaproic acid). Αμινογλουταιθιμίδιον (Aminoglutethimide). Αμινοπτερίνη νατριούχος (Aminopterin sodium). Αμινοσαλικυλικόν οξύ (Aminosalicylic acid). Αμιοδαρόνη (Amiodarone). Αμιφαιναζολη υδροχλωρική (Amiphenazole hydrochloride). Αμιτριπτυλινη (Amitriptyline). Αμιτριπτυλίνη οιμβονική (Amitriptyline embonate). Αμιτριπτυλινη υδροχλωρική (Amitriptyline hydrochloride). Αμμώνιον βρωμιούχον (Ammonium bromide). Αμοξυκιλλίνη (Amoxycillin). Αμοξυκιλλίνης τριυδρίτης (Amoxycillin trihydrate). Αμφομυκίνη (Amphomycin). Αμφοτερικίνη (Amphotericin). Αμπικιλλίνη (Ampicillin). Αμπικιλλίνη νατριούχος (Ampicillin sodium). Αμπικιλλίνης τριυδρίτης (Ampicillin trihydrate). Αμυλοβαρβιτόνη (Amylobarbitone). Αμυλοβαρβιτόνη νατριούχος (Amylobarbitone sodium): Αμυλοκαΐνη υδροχλωρική (Amylocaine hydrochloride) πλην οιαδήποτε χρήσις εκτός. οφθαλμικής τοπικώς. Ανκρόδ (Ancrod). Ανδροστερόνη (Androsterone). Αγγειοτενσίνης αμίδιον (Angiotensin, amide). Εκχύλισμα προσθίου λωβού υποφύσεως (Anterior pituitary extract). Τρυγικόν βαριοαντιμονύλιον (Antimony barium tartrate). Ηλεκτρικόν διμερκαπτοαντιμονύλιον (Antimony dimercaptosuccinate). Αντιμονιοθειομηλικόν λίθιον (Antimony lithium thiomalate). Αντιμόνιον πενταθειούχον (Antimony pentasulphide). Τρυγικόν καλιοαντιμονύλιον (Antimony potassium tartrate). Τρυγικόν νατριοαντιμονύλιον (Antimony sodium tartrate). Αντιμονοθειογλυκολλικόν νάτριον (Antimony sodium thioglucollate). Αντιμόνιον θειϊκόν (Antimony sulphate). Αντιμόνιον τριχλωριούχον (Antimony trichloride). Αντιμονίου τριοξείδιον (Antimony trioxide). Αντιμόνιον θειούχον (Antimony trisulphide). Απιόλη (Apiol). Απομορφίνη (Apomorphine). Απομορφίνη υδροχλωρική (Apomorphine hydrochloride). Απραμυκίνη (Apramycin). 166 Απραμυκίνη θειική (Apramycin sulphate). Απροβαρβιτόνη (Aprobarbitone). Απροβαρβιτόνη νατριούχος (Aprobarbitone sodium). Απροτινίνη (Aprotinin). Αρεκολίνη (Arecoline). Αρεκόλινο­ακεταρσόλη (Arecoline­acetarsol). Αρεκολίνη υδροβρωμική (Arecoline hydrobromide). Αρπρινοσίδη (Arprinocid) πλην κτηνιατρική χρήσις όταν προστίθεται εις τροφός πουλερικών διά πάχυνσιν, εις αναλογίαν μή υπερβαίνουσαν τα 90 μέρη ανά εκατομμύριον. Αρσανιλικόν οξύ (Arsanilic acid). Αρσενικόν (Arsenic). Αρσενικόν τριϊωδιούχον (Arsenic triodide). Αρσενικού τριοξείδιον (Arsenic trioxide). Αρσφαιναμίνη (Arsphenamine). Ατενολόλη (Atenolol). Ατροπίνη (Atropine) πλην εξωτερική χρήσις εκτός οφθαλμικής, εσωτερική χρήσις δι' εισπνοών, και Μ.Η.Δ. 0.3 χλστγρ. και Μ.Η.Δ. 1 χλστγρ. δΓ άλλας χρήσεις εσωτερικώς. Ατροπίνης μεθυλοβρωμίδιον (Atropine methobromide) πλην ως ατροπίνη εκτός Μ.Δ. 0.4 χλστγρ. και Μ.Η.Δ. 1.3 χλστγρ. Ατροπίνη μεθυλονιτρική (Atropine methonitrate) πλην ως ατροπίνης μεθυλοβρωμί­ διον. Ατροπίνης οξείδιον υδροχλωρικόν (Atropine oxide hydrochloride) πλην ως ατροπίνη εκτός Μ.Δ 0.360 χλστγρ. και Μ.Η.Δ. 1.2 χλστγρ. Ατροπίνη θειική (Atropine sulphate) πλην ως ατροπίνης οξείδιον υδροχλωρικόν. Αζακυκλονόλη (Azacyclonol). Αζακυκλονόλη υδροχλωρική (Azacyclonol hydrochloride). Αζαπερόνη (Azaperone). Αζαπροπαζόνη (Azapropazone). Αζαθειοπρίνη (Azathioprine). Αζαθειοπρίνη νατριούχος (Azathioprine sodium). Αζιδοκιλλίνη καλιούχος (Azidocillin potassium). Βακαμπικιλλίνη υδροχλωρική (Bacampicillin hydrochloride). Βακιτρακίνη (Bacitracin). Βακιτρακίνη μεθυλενοδισαλικυλική (Bacitracin methylene disalicylate). Βακιτρακίνη ψευδαργυρούχος (Bacitracin Zinc) πλην Μ.Π. 6,300,000 Δ.Μ./χλγρ. εις ζωοτρόφος ως αυξητικός παράγων. Βακλοφαίνη (Baclofen). Βαμβερμυκίνη (Bambermycin) πλην Μ.Π. 3% εις ζωοτροφάς ως αυξητικός παράγων. Βαρβιτόνη (Barbitone). Βαρβιτόνη νατριούχος (Barbitone sodium). Βάριον αθρακικόν (Barium carbonate). Βάριον χλωριούχον (Barium chloride). Βάριον θειούχον (Barium sulphide). Βεχλαμίδιον (Beclamide). Βεκλομεθαζόνη (Beclomethasone). Βεκλομεθαζόνη διπροπιονική (Beclomethasone dipropionate). Ευθαλείας πόα (Belladonna herb) πλην εξωτερική χρήσις και εσωτερική χρήσις Μ.Η.Δ. 1 χλστγρ. των ολικών αλκαλοειδών. Ευθαλείας ρίζα (Belladonna root) πλην ως πόα ευθαλείας. Βεμεγρίδιον (Bemegride). 167 Βεμεγρίδιον νατριούχον (Bemegride sodium). Βενακτίίζίνη υδροχλωρική = (Benactyzine hydrochloride). Βεναπρυζίνη υδροχλωρική (Benapryzine hydrochloride). Βενδροφλουαζίδιον (Bendrofluazide). Βενεθαμινοπενικιλλίνη (Benethamine penicillin). Βενοξαπροφαίνη (Benoxaprofen). Βενπεριδόλη (Benperidol). Βενζεραζίδιον (Benserazide). Βενζαθινοπενικιλλίνη (Benzathine penicillin). Βενζβρωμαρόνη (Benzbromarone). Βενζεξόλη υδροχλωρική (Benzhexol hydrochloride). Βενζιλώνιον βρωμιούχον (Benzilonium bromide). Βενζοκαΐνη (Beiizocaine) πλην οιαδήποτε χρήσις εκτός οφθαλμικής τοπικώς. Βενζοκταμίνη υδροχλωρική (benzoctamine hydrochloride). Βενζοιστρόλη (Benzoestrol). Βενζοϋλομετρονιδαζόλη (Benzoylmetronidazole). Ν-Βενζοϋλοσουλφανιλαμίδιον (N-Benzoyl sulphanilamide). Βενζοκιναμίδιον υδροχλωρικόν (Benzquinamide hydrochloride). Βενζοθειαζίδιον (Benzthiazide). Βενζοτροπίνη μεθανοσουλφονική (Benztropine mesylate). Βενζυλοπενικιλλίνη (Benzylpenicillin). Βενζυλοπενικιλλινικόν ασβέστιον (Benzylpenicillin calcium). Βηταϊστίνη υδροχλωρική (Betahistine hydrochloride). Βηταμεθαζόνη (Betamethasone). Βηταμεθαζόνη αδαμαντοϊκή (Betamethasone adamanteate). Βηταμεθαζόνη βενζοϊκή (Betamethasone benzoate). Βηταμεθαζόνη νατριοφωσφορική (Betamethasone sodium phosphate). Βηταμεθαζόνη βαλεριανική (Betamethasone valerate). Βετανεχόλη χλωριούχος (bethanechol chloride). Βετανιδίνη θειική (Bethanidine sulphate). Βιπεριδένη υδροχλωρική (Biperiden hydrochloride). Βιπεριδένη γαλακτική (Biperiden lactate). Γλυκοβιαρσόλη (Bismuth glycollylarsanilate). Βλεομυκίνη θειική (Bleomycin sulphate). Βολδενόνη ενδεκυλενική (Boldenone undecylenate). Βρετύλιον τοσυλικόν (Bretylium tosylate). Βρωμαζεπάμη (Bromazepam). Βρωμεξίνη υδροχλωρική (Bromhexine hydrochloride) πλην εσωτερική χρήσις εις την κτηνιατρικήν εις κατοικίδια πτηνά και περιστεράς. Βρωμοκριπτίνη μεθανοσουλφονική (Bromocriptine mesylate).
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Muscarinic Acetylcholine Receptor
    mAChR Muscarinic acetylcholine receptor mAChRs (muscarinic acetylcholine receptors) are acetylcholine receptors that form G protein-receptor complexes in the cell membranes of certainneurons and other cells. They play several roles, including acting as the main end-receptor stimulated by acetylcholine released from postganglionic fibersin the parasympathetic nervous system. mAChRs are named as such because they are more sensitive to muscarine than to nicotine. Their counterparts are nicotinic acetylcholine receptors (nAChRs), receptor ion channels that are also important in the autonomic nervous system. Many drugs and other substances (for example pilocarpineand scopolamine) manipulate these two distinct receptors by acting as selective agonists or antagonists. Acetylcholine (ACh) is a neurotransmitter found extensively in the brain and the autonomic ganglia. www.MedChemExpress.com 1 mAChR Inhibitors & Modulators (+)-Cevimeline hydrochloride hemihydrate (-)-Cevimeline hydrochloride hemihydrate Cat. No.: HY-76772A Cat. No.: HY-76772B Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic receptor agonist, is a candidate therapeutic drug for receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR The general pharmacol. properties of this drug on the The general pharmacol. properties of this drug on the gastrointestinal, urinary, and reproductive systems and other… gastrointestinal, urinary, and reproductive systems and other… Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 1 mg, 5 mg 1 mg, 5 mg AC260584 Aclidinium Bromide Cat. No.: HY-100336 (LAS 34273; LAS-W 330) Cat.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Poisons Act.Fm
    LAWS OF BRUNEI CHAPTER 114 POISONS Enactment No. 13 of 1956 Amended by S 103/1958 Enactment No. 6 of 1967 S 101/1979 1984 Edition, Chapter 114 Amended by S 16/1996 S 28/2001 GN 273/2002 REVISED EDITION 2015 B.L.R.O. 1/2015 LAWS OF BRUNEI Poisons CAP. 114 1 LAWS OF BRUNEI REVISED EDITION 2015 CHAPTER 114 POISONS ARRANGEMENT OF SECTIONS Section 1. Citation. 2. Interpretation. 3. Description of poisons. 4. Licensing Officers. 5. General prohibition with respect to importation and sale of poisons. 6. Prohibitions and provisions relating to sale of poisons. 7. Exemptions in respect of medicines. 8. Exemptions in respect of sale. 9. Possession of poisons. 10. Issue of licences. 11. Different kinds of licence. 12. Licences to be numbered and registered. 13. Annual list to be published. 14. Forms of licence. 15. Search and search warrants. 16. Powers of exemption. 17. Penalties. B.L.R.O. 1/2015 LAWS OF BRUNEI 2 CAP. 114 Poisons 18. Jurisdiction. 19. Prosecutions. 20. Prohibition of sale to persons under 18. 21. Rules. SCHEDULE — POISONS LIST ____________________________ LAWS OF BRUNEI Poisons CAP. 114 3 POISONS ACT An Act to regulate the importation, possession, manufacture, compounding, storage, transport and sale of poisons Commencement: 1st January 1983 [S 61/1957] Citation. 1. This Act may be cited as the Poisons Act. Interpretation. 2. In this Act, unless the context otherwise requires — “dentist” means a dentist licensed under the Medical Practitioners and Dentists Act (Chapter 112) and includes a Government dentist; “export”, in relation
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Pharmacy and Poisons Act 1979
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS ACT 1979 1979 : 26 TABLE OF CONTENTS PART I PRELIMINARY 1 Short title 2 Interpretation PART II THE PHARMACY COUNCIL 3 The Pharmacy Council 4 Membership of the Council 4A Functions of the Council 4B Protection from personal liability 4C Annual Report 5 Proceedings of the Council, etc PART III REGISTRATION OF PHARMACISTS 6 Offence to practise pharmacy if not registered 7 Registration as a pharmacist 7A Re-registration as non-practising member 7AA Period of validity of registration 8 Code of Conduct 9 Pharmacy Profession Complaints Committee 10 Investigation of complaint by Committee 10A Inquiry into complaint by Council 10B Inquiry by Council of its own initiative 11 Surrender of registration 12 Restoration of name to register 1 PHARMACY AND POISONS ACT 1979 13 Proof of registration 14 Appeals 14A Fees 14B Amendment of Seventh Schedule 15 Regulations for this part PART IV REGISTRATION OF PHARMACIES 16 Register of pharmacies 17 Registration of premises as registered pharmacies 18 Unfit premises: new applications 19 Unfit premises: registered pharmacies 20 Appeals 21 When certificates of unfitness take effect 22 Regulations for this Part PART V CONTROL OF PRESCRIPTIONS AND IMPORTATION 23 Prescriptions to be in a certain form 23A Validity of a prescription 24 Supply by registered pharmacist of equivalent medicines 25 Restrictions on the importation of medicines 26 Declaration relating to imported medicines [repealed] PART VI CONTROL OF DRUGS 27 Certain substances to be sold on prescription
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • University of Groningen Multi-Residue Analysis of Growth Promotors In
    University of Groningen Multi-residue analysis of growth promotors in food-producing animals Koole, Anneke IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 1998 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Koole, A. (1998). Multi-residue analysis of growth promotors in food-producing animals. s.n. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 25-09-2021 APPENDIX 1 OVERVIEW OF RELEVANT SUBSTANCES This appendix consists of two parts. First, substances that are relevant for the research presented in this thesis are given. For each substance CAS number (CAS), molecular weight (MW), bruto formula (formula) and if available UV maxima and alternative names are given. In addition, pKa values for the ß-agonists are listed, if they were available.
    [Show full text]
  • 有限公司 Testosterones
    ® 伊域化學藥業（香港）有限公司 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD Rm 1006, 10/F, Hewlett Centre, Tel: (852) 25412772 (4 lines) No. 52-54, Hoi Yuen Road, Fax: (852) 25423444 / 25420530 / 21912858 Kwun Tong, E-mail: [email protected] YICK -VIC 伊域 Kowloon, Hong Kong. Site: http://www.yickvic.com Testosterones Product Code CAS Product Name MIS-42658 1043-10-3 (8S,9S,10R,11S,13S,14S,17S)-11,17-DIHYDROXY-10,13,17-TRIMETHYL-2,6,7,8,9,11,12,14,15,16-DECAHYDRO-1H-CYCLOPENTA[A]PHENA NTHREN-3-ONE UNIE-13864 564-35-2 11-KETOTESTOSTERONE PH-1081U 17-ALPHA-HYDROXYTESTOSTERONE ACETATE MIS-39218 51154-09-7 17ALPHA-METHYLTESTOSTERONE 4,5-EPOXIDE PH-1121 72-63-9 17BETA-HYDROXY-17-METHYLANDROSTA-1,4-DIEN-3-ONE MIS-34565 5585-85-3 17BETA-HYDROXY-17-METHYLANDROSTA-4,6-DIEN-3-ONE PH-1081S 17BETA-HYDROXYANDROST-1-ENE-3-ONE TETRAHYDROPYRANYL ETHER PH-1081VA 1-TESTOSTERONE ETHYL CARBONATE PH-1081VB 1-TESTOSTERONE METHYL CARBONATE PH-1081VC 1-TESTOSTERONE PROPYL CARBONATE PH-1081HB 1-TESTOSTERONE UNDECANOATE UNIE-15172 2141-17-5 4-HYDROXYTESTOSTERONE UNIE-13597 62-99-7 6BETA-HYDROXYTESTOSTERONE SPI-4361 14531-84-1 6-DEHYDRO-19-NORTESTOSTERONE PH-1081PK 1057-07-4 ANDROSTANOLONE 17-BENZOATE Copyright © 2018 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD. All rights reserved. Page 1 of 3 Product Code CAS Product Name PH-1133 1605-89-6 BOLASTERONE UNIE-8525 CHLORDEHYDROMETHYLTESTOSTERONE PH-1081JA 1093-58-9 CLOSTEBOL PH-1081JB 855-19-6 CLOSTEBOL ACETATE SPI-0027GA 481-30-1 EPITESTOSTERONE SPI-0027GB EPITESTOSTERONE ACETATE PH-1081K 434-03-7 ETHISTERONE PH-1136B 76-43-7
    [Show full text]
  • Anhang Glossar Englisch–Deutsch
    Anhang Glossar Englisch–Deutsch Abadie’s sign Abadie-Zeichen, Adenohypophysis Adenohypophyse Dalrymple-Zeichen Adenoma of the thyroid gland Abdominal adiposity Fettverteilung, Schilddrüsenadenom abdominale Adenosine monophosphates Abdominal adipose tissue Fettgewebe, Adenosinmonophosphate viszerales Adenylate cyclase Adenylcyclase A-β-lipoproteinemia (ABL) Adipogenesis Lipogenese A-β-Lipoproteinämie Adipolysis Lipolyse Abnormal lipid metabolism Adiponectin Adiponectin Fettstoffwechselstörungen Adiposity Fettsucht Abnormal lipoprotein metabolism Adiposogenital dystrophia Fröhlich, Fettstoffwechselstörungen Morbus Accelerated hyperthyreoidism Krise, Adipsia Adipsie; Durstverhaltensstö- hyperthyreote rungen Acetatederivatives Essigsäure-Derivate Adolescent goitre Adoleszentenstruma Achard-Thiers syndrome Adrenal adenoma Nebennierenrinde- Achard-Thiers-Syndrom nadenom; Nebennierenrindentumoren, Acid-base balance Säure-Basen- benigne Haushalt Adrenal carcinoma Nebennierenrin- Acid-maltase deficiency Glykogenose, denkarzinom Typ II Adrenal cortex Nebennierenrinde Acidosis Azidose Adrenal cortex autoantibody Acne Akne Nebennierenrinden-Antikörper Acquired adrenogenital syndrome Adrenal gland Nebenniere adrenogenitales Syndrom, erworbenes Adrenal insufficiency Nebennierenrin- Acquired hyperlipoproteinemia deninsuffizienz Hyperlipoproteinämie, sekundäre Adrenal mass Nebennierentumoren Acromegaly Akromegalie Adrenal medulla Nebennierenmark; Acromicria Akromikrie Paraganglion, suprarenales Acropachy Akropachie Adrenal tumor Nebennierenrindentu- Activin
    [Show full text]